Vaxxas 新闻与活动
高管
生物技术
Vaxxas 拥有 2,350 家竞争者，其中包括 Incyte (美国(美洲))、Eurofins (卢森堡) 和 Anthos Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Reunion Neuroscience 刚刚宣布为 103 筹款数百万美元。 (公布2025八月8号).
- Shattuck Labs 刚刚宣布为 103 筹款数百万美元。 (公布2025八月8号).
- Impact Therapeutics 刚刚宣布为 55 筹款数百万美元。 (公布2025八月8号).
生物技术 行业的其他推荐联系人
消息
Vaxxas 的最新新闻稿
- Vaxxas Secures New U.S. Patent For its Needle-Free Vaccination Manufacturing Technology
- Newly Published Data Supports Effective Delivery of DNA-Based Vaccines Using Vaxxas’ High-Density Microarray Patch (HD-MAP) Delivery Technology
- Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery
- Vaxxas Appoints Leading Global Vaccine Experts as the Company Advances its Needle-Free Vaccination Technology Towards Late-Stage Clinical Trials
- Vaxxas and CEPI Advance US$4.8 million (AU$7.2 million) Program for Needle-Free Thermostable mRNA Vaccines
- Vaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination
- Vaxxas Expands Global Intellectual Property Portfolio for Exclusive Manufacture and Sale of Needle-Free Vaccination Technology
- News Article :: Vaxxas CEO David Hoey recognised by AmCham for bilateral collaboration in biotechnology
- Vaxxas Licenses Next-Generation Vaccine for Respiratory Syncytial Virus (RSV) from the United States National Institutes of Health (NIH)
- Vaxxas Initiates Phase I Clinical Trial of Pre-Pandemic Avian Influenza A Virus (H7N9) Vaccine Delivered Using Vaxxas’ Novel High-Density Microarray Patch (HD-MAP)
- View more press releases Close
